Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We retrospectively analyzed 216 patients undergoing a second allo-HCT for either relapse (56%) or graft failure (31%) between 2010 and 2017. Median age was 57.3 years (range 51–63). The same donor as for the first allo-HCT was chosen in 66 patients (31%) of whom 19 received an HLA-identical sibling donor, whereas a different donor was chosen for 116 patients (54%). Median follow-up was 40 months. Three-year overall survival (OS) and relapse-free survival (RFS) were 42% and 39%, respectively. Three-year non-relapse mortality (NRM) and relapse rates were 36% and 25%, respectively. Grade II-IV and III-IV acute GVHD occurred in 25% and 11% of patients, respectively, and the 3-year incidence of chronic GVHD was 33% including 14% for extensive grade. Graft-failure incidence at 1 year was 14%. In conclusion, our data suggest that a second allo-HCT is a potential option for patients failing first allo-HCT for MF albeit careful patient assessment is fundamental to identify individual patients who could benefit from this approach.
Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis : a retrospective study of the Chronic Malignancies Working Party of EBMT / M. Nabergoj, K. Mauff, M. Robin, N. Kroger, E. Angelucci, X. Poire, J. Passweg, A. Radujkovic, U. Platzbecker, S. Robinson, A. Rambaldi, S.L. Petersen, F. Stolzel, M. Stelljes, F. Ciceri, J. Mayer, M. Ladetto, L.C. de Wreede, L. Koster, P.J. Hayden, T. Czerw, J.C. Hernandez-Boluda, D. McLornan, Y. Chalandon, I. Yakoub-Agha. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - (2021 Apr 06). [Epub ahead of print]
Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis : a retrospective study of the Chronic Malignancies Working Party of EBMT
A. Rambaldi;
2021
Abstract
Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We retrospectively analyzed 216 patients undergoing a second allo-HCT for either relapse (56%) or graft failure (31%) between 2010 and 2017. Median age was 57.3 years (range 51–63). The same donor as for the first allo-HCT was chosen in 66 patients (31%) of whom 19 received an HLA-identical sibling donor, whereas a different donor was chosen for 116 patients (54%). Median follow-up was 40 months. Three-year overall survival (OS) and relapse-free survival (RFS) were 42% and 39%, respectively. Three-year non-relapse mortality (NRM) and relapse rates were 36% and 25%, respectively. Grade II-IV and III-IV acute GVHD occurred in 25% and 11% of patients, respectively, and the 3-year incidence of chronic GVHD was 33% including 14% for extensive grade. Graft-failure incidence at 1 year was 14%. In conclusion, our data suggest that a second allo-HCT is a potential option for patients failing first allo-HCT for MF albeit careful patient assessment is fundamental to identify individual patients who could benefit from this approach.File | Dimensione | Formato | |
---|---|---|---|
s41409-021-01271-4.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.11 MB
Formato
Adobe PDF
|
1.11 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.